EUCTR2014-003212-36-NL进行中（未招募）1 期
An Open-label, Phase 1b/2 Study of ACP-196 in Subjectswith Waldenström Macroglobulinemia - ACE-WM-001
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Men and women = 18 years of age.
- •Previously treated cohort only: A confirmed diagnosis of WM, which has relapsed after, or been refractory to = 1 prior therapy for WM and which requires treatment.
- •Previously untreated cohort only: A confirmed diagnosis of previously untreated WM in subjects who require treatment and do not want to receive chemoimmunotherapy or have comorbidities that would preclude chemoimmunotherapy such as:
- •oSymptomatic hyperviscosity with an IgM = 5,000 mg/dL
- •oDisease-related neuropathy
- •Serum concentration of IgM, as measured by serum protein
- •electrophoresis (SPEP) and immunofixation electrophoresis
- •(IFE), that exceeds the upper limits of normal or measurable
- •nodal WM (defined as the presence of =1 lymph node that
- •measures = 2.0 cm in the longest diameter and = 1.0 cm in the
- •longest perpendicular diameter).
- •Eastern Cooperative Oncology Group (ECOG) performance
- •status of = 2.
- •Agreement to use acceptable methods of contraception during
- •the study and for 30 days after the last dose of study drug if
- •sexually active and able to bear or beget children.
- •Agreement to refrain from sperm donation during the study and
- •for 30 days after the last dose of study drug.
- •Willing and able to participate in all required evaluations and
- •procedures in this study protocol including swallowing capsules
- •without difficulty.
- •Ability to understand the purpose and risks of the study and
- •provide signed and dated informed consent and authorization
- •to use protected health information (in accordanc
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1. Prior malignancy, except for adequately treated basal cell or
- •squamous cell skin cancer, in situ cervical cancer, or other cancer from
- •which the subject has been disease free for = 2 years or which will not
- •limit survival to < 2 years. Note: these cases must be discussed with the
- •Medical Monitor.
- •2. A life-threatening illness, medical condition or organ system
- •dysfunction which, in the investigator's opinion, could compromise the
- •subject's safety, interfere with the absorption or metabolism of ACP-196,
- •or put the study outcomes at undue risk.
- •3. Significant cardiovascular disease such as uncontrolled or
- •symptomatic arrhythmias, congestive heart failure, or myocardial
- •infarction within 6 months of screening, or any Class 3 or 4 cardiac
- •disease as defined by the New York Heart Association Functional
- •Classification, or left ventricular ejection fraction (LVEF) = 40%, or QTc
- •> 480 msec.
- •4. Malabsorption syndrome, disease significantly affecting
- •gastrointestinal function, or resection of the stomach or small bowel or
- •ulcerative colitis, symptomatic inflammatory bowel disease, or partial or
- •complete bowel obstruction.
- •5. Any immunotherapy within 4 weeks of first dose of study drug.
- •6. For subjects with recent chemotherapy or experimental therapy the
- •first dose of study drug must occur after 5 times the half-life of the
- •7. Prior exposure to a BCR inhibitor (eg, Btk, phosphoinositide-3 kinase
- •[PI3K]]], or Syk inhibitors) or BCL-2 inhibitors (eg, ABT-199).
- •8. Ongoing immunosuppressive therapy, including systemic or enteric
- •corticosteroids for treatment of WM or other conditions. Note: Subjects
- •may use topical or inhaled corticosteroids or low-dose steroids (= 10 mg
- •of prednisone or equivalent per day) as therapy for comorbid conditions.
- •During study participation, subjects may also receive systemic or enteric
- •corticosteroids as needed for treatment-emergent comorbid conditions.
- •9. Grade = 2 toxicity (other than alopecia) continuing from prior
- •anticancer therapy including radiation.
- •10. Known history of human immunodeficiency virus (HIV) or active
- •infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any
- •uncontrolled active systemic infection.
- •11. Major surgery within 4 weeks before first dose of study drug.
- •12. Uncontrolled autoimmune hemolytic anemia or idiopathic
- •thrombocytopenia purpura.
- •13. History of a bleeding diathesis (eg, hemophilia, von Willebrand
- •14. History of stroke or intracranial hemorrhage within 6 months before
- •the first dose of study drug.
- •15. Requires or receiving anticoagulation with warfarin or equivalent
- •vitamin K antagonists (eg, phenprocoumon) within 28 days of first dose
- •of study drug.
- •16. Requires treatment with long-acting proton pump inhibitors (eg,
- •omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole,
- •or pantoprazole).
- •17. Absolute neutrophil count (ANC) < 0.75 x 109/L or platelet count
- •<50 x 109/L. For subjects with disease involvement in the bone marrow,
- •ANC < 0.50 x 109/L or platelet count < 30 x 109/L.
- 另有 5 项未显示
研究者
相似试验
进行中（未招募）
不适用
A Trial to See the Effects of ACP-196 (the test drug) in Patients who haveWaldenström MacroglobulinemiaEUCTR2014-003212-36-FRAcerta Pharma BV88
进行中（未招募）
不适用
An Open-label, Phase 1b/2 Study of ACP-196 in Subjectswith Waldenström MacroglobulinemiaWaldenström MacroglobulinemiaMedDRA version: 18.0Level: PTClassification code 10047804Term: Waldenstrom's macroglobulinaemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10047805Term: Waldenstrom's macroglobulinaemia refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003212-36-ESAcerta Pharma BV88
已完成
2 期
An Open-label, Phase 2 Study of ACP-196 in Subjects with Waldenström MacroglobulinemiaWaldenström Macroglobulinemiamobus Waldenström10025320NL-OMON53142ACERTA PHARMA, BV7
进行中（未招募）
1 期
A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell LymphomaMedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851Mantle Cell LymphomaEUCTR2014-002117-28-NLAcerta Pharma BV117
进行中（未招募）
1 期
A Trial to See the Effects of ACP-196 (the test drug) in Patients who have Mantle Cell LymphomaMedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851Mantle Cell LymphomaEUCTR2014-002117-28-GBAcerta Pharma B.V.117